Croda International Plc CRDA.L
Composite 51/100; the shares have moved about 31% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 31/100 — a moderate mark against it.
Balance-sheet strength ranks 73/100 — a moderate point in its favour. Momentum ranks 73/100 — a moderate point in its favour. Quality ranks 51/100 — a slight point in its favour.
Valuation ranks 31/100 — a moderate mark against it. Growth ranks 31/100 — a moderate mark against it. Income ranks 43/100 — a slight mark against it.
What the company does Croda International Plc (CRDA.L) is a UK-based specialty chemicals company serving consumer care (beauty, home care, fragrances), life sciences (biologics delivery, crop protection), and industrial specialties (phase change materials, surfactants, textile finishes).
Key financials Revenue grew 3.9% but net income fell 99.0% YoY; margins compressed (gross 43.9%, operating -1.9%, net 3.6%). ROE 2.9%, ROA 2.1%, ROCE 15.3%. Debt/Equity 0.36, net debt/EBITDA 2.36, interest coverage 7.61. Dividend yield 3.8% with a 195.1% payout ratio.
Stock health Sideravia scores: Quality 45.2 (below avg), Growth 28.2 (weak), Strength 72.6 (strong), Valuation 34.7 (rich), Momentum 70.2 (positive), Income 55.5. Piotroski F-Score 6/9, Altman Z 4.24, current ratio 2.57.
Price vs fair value The stock trades at a PREMIUM of 51.00% versus our fair-value estimate and a discount of 10.75% versus the analyst 12-month target. - Trading at a 51.00% premium to fair value (our fair-value estimate 1577.07) - Trading at a 10.75% discount to 14-analyst consensus target 3566.07 - Valuation percentile 34.7/100 (richly valued) - Forward P/E 16.95 vs trailing 67.97 (multiple compression) - H1 earnings call highlights discussed margin pressure (MarketBeat)
Looking forward Forward PEG 0.06 suggests potential undervaluation vs long-term growth, but weak profitability and high payout ratio warrant caution. Momentum remains positive (12m 23.99%) with RSI 67.30.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.